Y
Yao Zhao
Researcher at Fudan University
Publications - 53
Citations - 1449
Yao Zhao is an academic researcher from Fudan University. The author has contributed to research in topics: Glioma & Angiogenesis. The author has an hindex of 19, co-authored 52 publications receiving 1196 citations.
Papers
More filters
Journal ArticleDOI
Recurrent gain-of-function USP8 mutations in Cushing's disease
Zengyi Ma,Zhijian Song,Jianhua Chen,Yongfei Wang,Shiqi Li,Liangfu Zhou,Ying Mao,Yiming Li,Ronggui Hu,Zhaoyun Zhang,Hongying Ye,Ming Shen,Xuefei Shou,Zhiqiang Li,Hong Peng,Qingzhong Wang,Daizhan Zhou,Xiaolan Qin,Jue Ji,Jie Zheng,Hong Chen,Yin Wang,Dao-Ying Geng,Weijun Tang,Chaowei Fu,Zhifeng Shi,Yichao Zhang,Zhao Ye,Wenqiang He,Qilin Zhang,Qisheng Tang,Rong Xie,Jiawei Shen,Zujia Wen,Juan Zhou,Tao Wang,Shan Huang,Huijia Qiu,Nidan Qiao,Yi Zhang,Li Pan,Weimin Bao,Yingchao Liu,Chuanxin Huang,Yongyong Shi,Yao Zhao +45 more
TL;DR: Somatic gain-of-function USP8 mutations are common and contribute to ACTH overproduction in Cushing's disease and inhibition of USP9 or EGFR is promising for treating USp8-mutated corticotrophin adenoma.
Journal ArticleDOI
The genome-wide mutational landscape of pituitary adenomas.
Journal ArticleDOI
Association of Sequence Variants on Chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) With Glioma Susceptibility in a Chinese Population
Hongyan Chen,Yuanyuan Chen,Yao Zhao,Weiwei Fan,Keke Zhou,Yanhong Liu,Liangfu Zhou,Ying Mao,Qingyi Wei,Jianfeng Xu,Daru Lu +10 more
TL;DR: This study provides further evidence for 3 glioma susceptibility regions at 20q13.33, 11q23.3, and 5p15.33 in Chinese populations.
Journal ArticleDOI
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
TL;DR: Presurgical long-acting octreotide treatment effectively reduces tumor size and invasion, which helps enhance early remission rates of invasive macroadenomas by transsphenoidal surgery, but does not appear to improve the long-term cure rate.
Journal ArticleDOI
Surgical Strategies in Treating Brainstem Cavernous Malformations
TL;DR: Surgical resection remains the primary therapeutic option after careful patient screening and preoperative planning and the National Institutes of Health Strength Scale is optimal for evaluating the natural history and surgical effect of patients harboring BSCMs.